文献速递前列腺癌

PSMA-PET加入常用列线图预测前列腺癌盆腔淋巴结转移的外部验证与增益

External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study.
PubMed 文献 · Eur Urol · 2021-05-21

该国际多中心研究纳入757例接受机器人辅助根治性前列腺切除术及扩大盆腔淋巴结清扫的局限性前列腺癌患者,评估Briganti 2017、MSKCC和Briganti 2019列线图的预测性能,并分析加入PSMA-PET后的增益。结果显示,加入PSMA-PET后三个列线图的区分度均显著提高,决策曲线分析显示净获益增加。

要点

  • Briganti 2017、MSKCC、Briganti 2019列线图原始AUC分别为0.70、0.71、0.76。
  • 加入PSMA-PET后交叉验证AUC分别提高至0.76、0.77、0.82。
  • PSMA-PET与pN1疾病显著相关(p < 0.001),并增加决策曲线净获益。

核心结论

  • 将PSMA-PET加入现有列线图可显著改善对盆腔淋巴结转移的预测性能。

主要发现

  • 186/757例(25%)患者术后病理证实为pN1疾病。
  • Briganti 2017、MSKCC、Briganti 2019列线图的AUC分别为0.70(95%CI 0.64-0.77)、0.71(95%CI 0.65-0.77)、0.76(95%CI 0.71-0.82)。
  • 加入PSMA-PET后,三个列线图的交叉验证AUC分别提高至0.76(95%CI 0.70-0.82)、0.77(95%CI 0.72-0.83)、0.82(95%CI 0.76-0.87)。
  • PSMA-PET加入列线图后与pN1疾病显著相关(p < 0.001)。
  • 决策曲线分析显示,加入PSMA-PET后三个列线图的净获益均增加。

临床怎么用

  • 在术前预测盆腔淋巴结转移时,可考虑将PSMA-PET结果整合入现有列线图以提高预测准确性。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Different nomograms exist for the preoperative prediction of pelvic lymph-node metastatic disease in individual patients with prostate cancer (PCa). These nomograms do not incorporate modern imaging techniques such as prostate-specific membrane antigen (PSMA) positron emission tomography (PET). OBJECTIVE: To determine the predictive performance of the Briganti 2017, Memorial Sloan Kettering Cancer Center (MSKCC), and Briganti 2019 nomograms with the addition of PSMA-PET in an international, multicenter, present-day cohort of patients undergoing robot-assisted radical prostatectomy (RARP) and extended pelvic lymph-node dissection (ePLND) for localized PCa. DESIGN, SETTING, AND PARTICIPANTS: All 757 eligible patients who underwent a PSMA-PET prior to RARP and ePLND in three reference centers for PCa surgery between January 2016 and November 2020 were included. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Performance of the three nomograms was assessed using the receiver operating characteristic curve-derived area under the curve (AUC), calibration plots, and decision curve analyses. Subsequently, recalibration and addition of PSMA-PET to the nomograms were performed. RESULTS AND LIMITATIONS: Overall, 186/757 patients (25%) had pelvic lymph-node metastatic (pN1) disease on histopathological examination. AUCs of the Briganti 2017, MSKCC, and Briganti 2019 nomograms were 0.70 (95% confidence interval [95% CI]: 0.64-0.77), 0.71 (95% CI: 0.65-0.77), and 0.76 (95% CI: 0.71-0.82), respectively. PSMA-PET findings showed a significant association with pN1 disease when added to the nomograms (p < 0.001). Addition of PSMA-PET substantially improved the discriminative ability of the models yielding cross-validated AUCs of 0.76 (95% CI: 0.70-0.82), 0.77 (95% CI: 0.72-0.83), and 0.82 (95% CI: 0.76-0.87), respectively. In decision curve analyses, the addition of PSMA-PET to the three nomograms resulted in increased net benefits. CONCLUSIONS: The addition of PSMA-PET to the previously developed nomograms showed substantially improved predictive performance, which suggests that PSMA-PET is a likely future candidate for a modern predictive nomogram. PATIENT SUMMARY: Different tools have been developed to individualize the prediction of prostate cancer spread to lymph nodes before surgery. We found that the inclusion of modern imaging (prostate-specific membrane antigen positron emission tomography) improved substantially the overall performance of these prediction tools.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Meijer D, van Leeuwen PJ, Roberts MJ, et al. External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study. Eur Urol. 2021. PMID: 34024652. doi:10.1016/j.eururo.2021.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。